Abstract | INTRODUCTION:
Erectile dysfunction is increasingly common with advancing age, yet sexual activity and intimacy are important to elderly men. AIM: To assess the efficacy and tolerability of tadalafil in men over the age of 65 years. METHOD: In this multicenter open-label study, 188 men (mean age = 71.6 years) who were over age 65 and did not have diabetes mellitus or clinical depression received tadalafil 20 mg, taken on demand, for up to 12 weeks. MAIN OUTCOME MEASURES: Efficacy was assessed using the International Index of Erectile Function (IIEF) and Sexual Encounter Profile (SEP). Psychosocial outcomes were evaluated using the Psychological and Interpersonal Relationship Scale (PAIRS). RESULTS:
Tadalafil treatment significantly improved all domains of the IIEF from baseline, including the erectile function (EF) domain (change = 8.8, end point = 21.6; P < 0.001). Mean per-patient percentage of "yes" responses to SEP questions concerning successful penetration (SEP2; change = 33.5%, end point = 73.5%; P < 0.001) and successful intercourse (SEP3; change = 39.6%, end point = 59.6%; P < 0.001) also improved significantly from baseline. Forty percent of the patients with baseline EF scores < 26 had normal EF (IIEF-EF domain scores > or = 26) at end point, and 81% reported improved erections in the Global Assessment Questionnaire. At least 56% of attempts at sexual intercourse were successfully completed (SEP3) at all time intervals up to 36 hours after tadalafil administration. The patients also experienced significant improvement in both the sexual self-confidence and spontaneity domains of the PAIRS. Tadalafil was well tolerated, with < 5% of the patients discontinuing because of adverse events. CONCLUSION:
Tadalafil 20 mg was effective and well tolerated in elderly men with ED.
|
Authors | Ira D Sharlip, Bryan P Shumaker, Lawrence S Hakim, Evan Goldfischer, Fanni Natanegara, David G Wong |
Journal | The journal of sexual medicine
(J Sex Med)
Vol. 5
Issue 3
Pg. 716-25
(Mar 2008)
ISSN: 1743-6109 [Electronic] Netherlands |
PMID | 18304286
(Publication Type: Controlled Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carbolines
- Phosphodiesterase Inhibitors
- Tadalafil
|
Topics |
- Aged
- Aged, 80 and over
- Carbolines
(administration & dosage)
- Dose-Response Relationship, Drug
- Erectile Dysfunction
(drug therapy, psychology)
- Humans
- Male
- Patient Satisfaction
(statistics & numerical data)
- Penile Erection
(drug effects)
- Phosphodiesterase Inhibitors
(administration & dosage)
- Research Design
- Severity of Illness Index
- Surveys and Questionnaires
- Tadalafil
- Treatment Outcome
|